• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

诊断挑战的跨学科方法:心脏轻链(AL)淀粉样变性、多发性骨髓瘤和导管原位癌的病例研究

Interdisciplinary Approach to Diagnostic Challenges: A Case Study of Cardiac Amyloid Light-Chain (AL) Amyloidosis, Multiple Myeloma, and Ductal Carcinoma In Situ.

作者信息

Tashima Yuko, Setoyama Koshi, Higashi Takehiro, Nawata Aya, Tanaka Fumihiro

机构信息

Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, JPN.

Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.

出版信息

Cureus. 2025 May 1;17(5):e83299. doi: 10.7759/cureus.83299. eCollection 2025 May.

DOI:10.7759/cureus.83299
PMID:40452673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12127001/
Abstract

Amyloid light-chain (AL) amyloidosis is a disorder caused by abnormal plasma cells, and it may develop either as a primary disease or as a secondary condition associated with multiple myeloma. Due to the absence of specific clinical symptoms, its diagnosis is often challenging. Here, we present a case of cardiac amyloidosis secondary to multiple myeloma, incidentally complicated by ductal carcinoma in situ (DCIS). Although the breast cancer was diagnosed as stage 0 (DCIS), the patient's heart failure symptoms worsened following surgical resection. As a result, further evaluation by the cardiology department was performed, leading to a diagnosis of cardiac amyloidosis. Subsequently, a hematology consultation was obtained, and bone marrow biopsy revealed that clonal plasma cells accounted for more than 60% of bone marrow cellularity, confirming a diagnosis of multiple myeloma. The patient received daratumumab + bortezomib + cyclophosphamide + dexamethasone therapy, achieved a partial response, and has been alive for >2 years. This case is a valuable example of a patient who experienced a gradual onset of the symptoms of amyloidosis, including palpitations, pleural effusion, right and left heart failure, before a diagnosis could be made. It took a total of eight departments to make a diagnosis, as it was challenging. Even if no abnormalities are observed in a single examination, it is important to listen carefully to patient complaints, repeat the examination if necessary, and work with multiple departments to provide treatment.

摘要

淀粉样轻链(AL)淀粉样变性是一种由异常浆细胞引起的疾病,它可能作为原发性疾病出现,也可能作为与多发性骨髓瘤相关的继发性疾病发展。由于缺乏特异性临床症状,其诊断往往具有挑战性。在此,我们报告一例继发于多发性骨髓瘤的心脏淀粉样变性病例,该病例意外合并原位导管癌(DCIS)。尽管乳腺癌被诊断为0期(DCIS),但患者在手术切除后心力衰竭症状恶化。因此,心内科进行了进一步评估,从而诊断为心脏淀粉样变性。随后,进行了血液科会诊,骨髓活检显示克隆性浆细胞占骨髓细胞成分的60%以上,确诊为多发性骨髓瘤。该患者接受了达雷妥尤单抗+硼替佐米+环磷酰胺+地塞米松治疗,取得了部分缓解,目前已存活超过2年。该病例是一个有价值的例子,说明患者在确诊前经历了淀粉样变性症状的逐渐出现,包括心悸、胸腔积液、左右心力衰竭。由于诊断具有挑战性,总共涉及八个科室才得以确诊。即使在单次检查中未观察到异常,认真听取患者主诉、必要时重复检查并与多个科室合作进行治疗也很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/892257754706/cureus-0017-00000083299-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/fafb67ecf18d/cureus-0017-00000083299-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/5fd70d5cfce8/cureus-0017-00000083299-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/629b30e6a87c/cureus-0017-00000083299-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/892257754706/cureus-0017-00000083299-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/fafb67ecf18d/cureus-0017-00000083299-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/5fd70d5cfce8/cureus-0017-00000083299-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/629b30e6a87c/cureus-0017-00000083299-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/137a/12127001/892257754706/cureus-0017-00000083299-i04.jpg

相似文献

1
Interdisciplinary Approach to Diagnostic Challenges: A Case Study of Cardiac Amyloid Light-Chain (AL) Amyloidosis, Multiple Myeloma, and Ductal Carcinoma In Situ.诊断挑战的跨学科方法:心脏轻链(AL)淀粉样变性、多发性骨髓瘤和导管原位癌的病例研究
Cureus. 2025 May 1;17(5):e83299. doi: 10.7759/cureus.83299. eCollection 2025 May.
2
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.达雷妥尤单抗、泊马度胺和地塞米松作为系统性轻链淀粉样变伴晚期心脏受累患者自体干细胞移植的桥接治疗。
J Oncol Pharm Pract. 2019 Jun;25(4):1021-1025. doi: 10.1177/1078155218815305. Epub 2018 Nov 26.
3
[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].[硼替佐米、地塞米松和环磷酰胺或含阿霉素方案治疗AL淀粉样变性的结果]
Vnitr Lek. 2012 Dec;58(12):896-903.
4
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].[与单克隆丙种球蛋白病相关的肾脏疾病:诊断与治疗进展]
Presse Med. 2012 Mar;41(3 Pt 1):276-89. doi: 10.1016/j.lpm.2011.11.008. Epub 2012 Jan 13.
5
AL type cardiac amyloidosis: a devastating fatal disease.AL型心脏淀粉样变性:一种毁灭性的致命疾病。
J Community Hosp Intern Med Perspect. 2021 May 10;11(3):407-412. doi: 10.1080/20009666.2021.1915547. eCollection 2021.
6
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.达雷妥尤单抗:在新诊断的系统性轻链淀粉样变性中的应用评价。
Drugs. 2022 Apr;82(6):683-690. doi: 10.1007/s40265-022-01705-3.
7
Extracorporeal membrane oxygenation as bridge-to-decision in acute heart failure due to systemic light-chain amyloidosis.体外膜肺氧合作为系统性轻链淀粉样变性所致急性心力衰竭的决策桥梁。
Am J Case Rep. 2015 Mar 24;16:174-81. doi: 10.12659/AJCR.892772.
8
[Heart failure secondary to amyloidosis AL: diagnosis and treatment].[AL型淀粉样变性所致心力衰竭:诊断与治疗]
Medicina (B Aires). 2023;83(5):811-815.
9
Multiple myeloma initially manifesting as a solitary deep ulcer on the tongue: a case study and literature review.多发性骨髓瘤初发表现为舌部单发深大溃疡 1 例并文献复习
Eur J Dermatol. 2023 Dec 1;33(6):618-623. doi: 10.1684/ejd.2023.4628.
10
[Heart transplantation and the subsequent treatment of AL amyloidosis].[心脏移植与AL淀粉样变性的后续治疗]
Vnitr Lek. 2013 Feb;59(2):136-47.

本文引用的文献

1
Breast Imaging: what women & healthcare professionals need to know.乳腺影像学:女性和医疗保健专业人员需要了解的知识。
Curr Probl Diagn Radiol. 2025 Jan-Feb;54(1):51-64. doi: 10.1067/j.cpradiol.2024.10.036. Epub 2024 Nov 26.
2
The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis.重视通路以促进心脏淀粉样变性患者的早期诊断和治疗。
Ther Adv Cardiovasc Dis. 2023 Jan-Dec;17:17539447231216318. doi: 10.1177/17539447231216318.
3
Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
免疫球蛋白轻链淀粉样变性:2024年诊断、预后及治疗的最新进展
Am J Hematol. 2024 Feb;99(2):309-324. doi: 10.1002/ajh.27177. Epub 2023 Dec 14.
4
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.达雷妥尤单抗治疗免疫球蛋白轻链淀粉样变性。
N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.
5
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.心脏淀粉样变性的诊断与治疗:欧洲心脏病学会心肌与心包疾病工作组的立场声明
Eur Heart J. 2021 Apr 21;42(16):1554-1568. doi: 10.1093/eurheartj/ehab072.
6
Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease.淀粉样变性——一种被低估的疾病的诊断与治疗。
Dtsch Arztebl Int. 2020 Mar 6;117(10):159-166. doi: 10.3238/arztebl.2020.0159.
7
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.达雷妥尤单抗联合 CyBorD 方案治疗初诊淀粉样变性多发性骨髓瘤患者:ANDROMEDA 的安全性预试验结果。
Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460.
8
Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan.日本741例系统性轻链型淀粉样变患者的全国性调查。
Intern Med. 2018 Jan 15;57(2):181-187. doi: 10.2169/internalmedicine.9206-17. Epub 2017 Nov 1.
9
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.2000年至2014年间新诊断的AL淀粉样变性患者的预后改善:突破早期死亡的瓶颈
Blood. 2017 Apr 13;129(15):2111-2119. doi: 10.1182/blood-2016-11-751628. Epub 2017 Jan 26.
10
AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.AL(轻链)心脏淀粉样变:诊断与治疗的综述。
J Am Coll Cardiol. 2016 Sep 20;68(12):1323-41. doi: 10.1016/j.jacc.2016.06.053.